<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351998</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00140789</org_study_id>
    <secondary_id>R01AR071263</secondary_id>
    <nct_id>NCT03351998</nct_id>
  </id_info>
  <brief_title>Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity</brief_title>
  <official_title>Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test how different doses of a statin, Lipitor, affect muscle
      health and function, and cardiovascular fitness.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in mitochondrial respiratory function</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VO2 max</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Citrate synthase activity</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mitochondrial Diseases</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receiving matching placebo oral tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose statin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Lipitor 20Mg Tablet to take daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose statin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Lipitor 80Mg Tablet to take daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipitor 20Mg Tablet</intervention_name>
    <description>20 mg/day pills.</description>
    <arm_group_label>Low dose statin</arm_group_label>
    <other_name>atorvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipitor 80Mg Tablet</intervention_name>
    <description>80 mg/day pills.</description>
    <arm_group_label>High dose statin</arm_group_label>
    <other_name>atorvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Matching placebo pill.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) between 25-43

          -  Weight stable (no more than 5% change in body weight the previous 3 months)

          -  &gt;5% risk for a cardiovascular event in the next 10 years according to the 2013
             American College of Cardiology/American Heart Association risk calculator and/or 2 out
             of 5 metabolic syndrome risk factors (Triglycerides ≥ 150 mg/dL; HDL ≤ 40 mg/dL;
             Glucose ≥ 100mg/dL; Waist Circumference ≥ 102cm for males, 88cm for females; Blood
             pressure: ≥ 130mmHg systolic and/or 85mmHg diastolic or being treated for
             hypertension) and/or LDL-Cholesterol &gt;120 mg/dl.

          -  Stable doses of medications for 90 days

          -  Willing to stop all Nonsteroidal Antiinflammatory Drugs (NSAIDs) and aspirin for 7
             days prior to muscle biopsy

        Exclusion Criteria:

          -  Smoking

          -  Previous use of statins

          -  Use of other medications or supplements that affect lipid profiles or body weight in
             the last 6 months (e.g., fibric acids, bile acid sequestrants, nicotinic acids, fish
             oil)

          -  Diagnosis of chronic diseases including CVD, other metabolic diseases (e.g., thyroid),
             current diagnosis and active treatment of cancer, HIV, or acquired immunodeficiency
             syndrome.

          -  Diagnosis of type 1 or type 2 diabetes at the time of screening (fasting blood glucose
             &gt;126mg/dL). If evidence of type 2 diabetes outcome measures is detected during the
             course of the study (fasting glucose &gt; 126 mg/dl or HbA1c &gt; 6.5%) we will notify the
             participant to contact their physician.

          -  History of abnormal bleeding problems

          -  Currently taking (within the last 10 days) anti-platelet medication (Plavix),
             Warfarin, and other anti-coagulants (eliquis, pradaxa, and xarelto) medications.

          -  &gt;2 fold upper normal limit (UNL) for alanine aminotransferase (ALT) or creatinine

          -  Women who are pregnant or breastfeeding

          -  Individuals with polymorphisms (SLCO1B1 and GATM) known to be associated with
             susceptibility for statin induced myopathies (tested at screening)

          -  Currently enrolled in another research study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Thyfault, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara Amat, MS</last_name>
    <phone>913-945-8834</phone>
    <email>camatfernandez@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Brophy</last_name>
    </contact>
    <investigator>
      <last_name>Darrell Neufer, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin sensitivity</keyword>
  <keyword>cardiorespiratory fitness</keyword>
  <keyword>skeletal muscle mitochondrial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

